MWM
GPCR icon

Mission Wealth Management’s Structure Therapeutics GPCR Stock Holding History

Mission Wealth Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$366K Sell
7,583
-2,000
-21% -$137K 0.01% 568
2025
Q4 		$666K Hold
9,583
– – 0.01% 420
2025
Q3 		$268K Buy
+9,583
New +$191K 0.01% 613

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Mission Wealth Management's GPCR Position: Q1 2026 in Review

Mission Wealth Management reduced its Structure Therapeutics (GPCR) stake by 21% in Q1 2026, selling an estimated $137K and leaving 7,583 shares worth $366K. The position accounts for 0.01% of the portfolio, ranked #568.

Mission Wealth Management first reported a position in GPCR in Q3 2025 and has held it in 3 quarters since. The position peaked at $666K in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

  • Mission Wealth Management held 7,583 shares of Structure Therapeutics worth $366K as of Q1 2026.
  • Mission Wealth Management sold 2,000 Structure Therapeutics shares in Q1 2026, an estimated $137K.
  • Structure Therapeutics made up 0.01% of Mission Wealth Management's portfolio in Q1 2026, its #568 holding.
  • Mission Wealth Management first reported a position in Structure Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Mission Wealth Management's Structure Therapeutics position peaked at $666K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Mission Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.